RxDoctor Payments DataLook up a doctor →

Mitchell Sorsby, MD

Endocrinology, Diabetes & Metabolism · Plano, TXNPI 1154375939

Payments from drug & device makers

$945,211in general payments, 2019–2025

Across 2,485 payments — averaging $380.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$455K
  • Novo Nordisk$175K
  • Sanofi-aventis U.S. LLC$91K
  • Radius Health, Inc.$81K
  • Amarin Pharma, Inc.$27K
  • AstraZeneca$24K
  • plus $92K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC1,098$454,676
Novo Nordisk300$175,449
Sanofi-aventis U.S. LLC166$90,701
Radius Health, Inc.157$81,171
Amarin Pharma, Inc.89$27,477
AstraZeneca(2 entities)85$23,687
Johnson & Johnson43$18,793
Merck51$16,801
Boehringer Ingelheim50$13,895
Dexcom, Inc.30$11,018
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$6,486
Abbott32$5,587
Tandem Diabetes Care, Inc.19$4,717
Mannkind Corporation51$4,703
Vivus LLC8$3,721
Amgen(2 entities)58$1,266
AbbVie47$741
Insulet Corporation27$699
Xeris Pharmaceuticals, Inc.18$374
Medtronic(2 entities)8$349
Corcept Therapeutics9$338
Bayer14$329
Esperion Therapeutics, Inc.9$266
Amneal Pharmaceuticals LLC14$226
IBSA Pharma Inc.12$172
Companion Medical, Inc.5$172
Gilead1$113
Eton Pharmaceuticals, Inc.2$112
Cequr Corporation3$100
Valeritas, Inc.6$92
Pfizer6$87
Zealand Pharma US, Inc.6$84
Antares Pharma, Inc.4$67
Kowa Pharmaceuticals America, Inc.5$66
Shire North American Group Inc4$65
Rhythm Pharmaceuticals, Inc.2$53
Ultragenyx Pharmaceutical Inc.3$41
Intuity Medical Inc2$39
Recordati_rare_diseases_inc.2$35
Astellas Pharma US Inc2$35
Ascensia Diabetes Care US Inc.2$29
Althera Pharmaceuticals LLC2$29
Madrigal Pharmaceuticals1$29
Tolmar Pharmaceuticals, Inc.1$25
Acerus Pharmaceuticals Corporation2$25
Ascendis Pharma Endocrinology Inc1$24
BETA Bionics, Inc.2$24
Aytu Biopharma, Inc.2$24
Vifor Pharma, Inc.1$22
Sun Pharmaceutical Industries Inc.1$22
Amryt Pharma Holdings Ltd1$21
Alvogen Inc1$21
Kyowa Kirin, Inc.1$19
Amphastar Pharmaceuticals, Inc.1$19
Acella Pharmaceuticals, LLC1$17
Agios Pharmaceuticals, Inc.1$17
BD1$16
Lifescan, Inc.1$14
Arbor Pharmaceuticals, Inc.1$11

How this compares

$945,211 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$78,518
Medicare patients
298
Services billed
2,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Plano

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →